Orthogonally Protected Artificial Amino Acid as Tripod Ligand for Automated Peptide Synthesis and Labeling with [<sup>99m</sup>Tc(OH<sub>2</sub>)<sub>3</sub>(CO)<sub>3</sub>]<sup>+</sup>

Abstract

1,2-Diamino-propionic acid (Dap) is a very strong chelator for the [<sup>99m</sup>Tc­(CO)<sub>3</sub>]<sup>+</sup> core, yielding small and hydrophilic complexes. We prepared the lysine based Dap derivative l-Lys­(Dap) in which the ε-NH<sub>2</sub> group was replaced by the tripod through conjugation to its α-carbon. The synthetic strategy produced an orthogonally protected bifunctional chelator (BFC). The -NH<sub>2</sub> group of the α-amino acid portion is Fmoc- and the -NH<sub>2</sub> of Dap are Boc-protected. Fmoc-l-Lys­(Dap­(Boc)) was either conjugated to the N- and C-terminus of bombesin BBN(7–14) or integrated into the sequence using solid-phase peptide synthesis (SPPS). We also replaced the native lysine in a cyclic RGD peptide with l-Lys­(Dap). For all peptides, quantitative labeling with the [<sup>99m</sup>Tc­(CO)<sub>3</sub>]<sup>+</sup> core at a 10 μM concentration in PBS buffer (pH = 7.4) was achieved. For comparison, the rhenium homologues were prepared from [Re­(OH<sub>2</sub>)<sub>3</sub>(CO)<sub>3</sub>]<sup>+</sup> and Lys­(Dap)-BBN(7–14) or cyclo-(RGDyK­(Dap)), respectively. Determination of integrin receptor binding showed low to medium nanomolar affinities for various receptor subtypes. The IC<sub>50</sub> of cyclo-(RGDyK­(Dap­[Re­(CO)<sub>3</sub>])) for α<sub>v</sub>β<sub>3</sub> is 7.1 nM as compared to 3.1 nM for nonligated RGD derivative. Biodistribution studies in M21 melanoma bearing nude mice showed reasonable α<sub>v</sub>β<sub>3</sub>-integrin specific tumor uptake. Altogether, orthogonally protected l-Lys­(Dap) represents a highly versatile building block for integration in any peptide sequence. Lys­(Dap)-precursors allow high-yield <sup>99m</sup>Tc-labeling with [<sup>99m</sup>Tc­(OH<sub>2</sub>)<sub>3</sub>(CO)<sub>3</sub>]<sup>+</sup>, forming small and hydrophilic complexes, which in turn leads to peptide radiopharmaceuticals with excellent in vivo characteristics

    Similar works

    Full text

    thumbnail-image

    Available Versions